MAXAIR
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXAIR is a metered-dose aerosol inhaler approved in 1992 by NDA pathway, marketed by Bausch + Lomb. The specific mechanism of action, pharmacologic class, and clinical indications are not disclosed in available data. The product is administered via inhalation for respiratory management.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting defensive strategies and potential workforce rationalization as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXAIR currently has zero linked job openings, reflecting its mature lifecycle status and approaching loss-of-exclusivity. Roles supporting this product are limited to maintenance and defense strategies rather than growth initiatives or innovation.
Brand ManagerField Sales Representative
Worked on MAXAIR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.